Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
TERN-601
/
Terns Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
TERN-601
/
Terns Pharma
TERN-601, a Novel Oral GLP-1R Agonist, Suppresses Food Intake and Improves Glucose Tolerance in Transgenic Mice Expressing Human GLP-1 Receptor
(Poster Halls B-C; [Board No. 767]) - Apr 10, 2023 - Abstract #ADA2023ADA_1355;
In transgenic mice expressing human GLP-1R, single oral doses of TERN-601 significantly suppressed food intake and improved glucose tolerance. Together these data support the continued development of TERN-601.